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Introduction
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous
group of tumors with different clinical, immunophenotypic,
and genetic abnormalities as well as highly variable progno-
sis.1 Identifying distinctive subgroups within the DLBCL cat-
egory can assist with prognostication and therapeutic strate-
gy. According to gene expression profile (GEP), DLBCL can be
divided into germinal center B-cell (GCB), activated B-cell
(ABC), and unclassified subtypes,2-4 with different outcomes
after treatment with rituximab, cyclophosphamide, doxoru-
bicin, vincristine, and prednisone (R-CHOP).3-5
The t(14;18)(q32;q21) has been identified in 18–20% of
patients with de novo DLBCL.6-9 Rarely, BCL2 is translocated to
Ig light chain (IgK, IgL) loci, as a part of t(2;18)(p11;q21.3) or
t(18;22)(q21.3;q11), similarly resulting in Bcl-2 overexpression.
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Diffuse large B-cell lymphoma can be classified by gene expression profiling into germinal center and activated B-
cell subtypes with different prognoses after rituximab-CHOP. The importance of previously recognized prognostic
markers, such as Bcl-2 protein expression and BCL2 gene abnormalities, has been questioned in the new therapeu-
tic era. We analyzed Bcl-2 protein expression, and BCL2 and MYC gene abnormalities by interphase fluorescence
in situ hybridization in 327 patients with de novo disease treated with rituximab-CHOP. Isolated BCL2 and MYC
rearrangements were not predictive of outcome in our patients as a whole, but only in those with the germinal
center subtype of lymphoma. The prognostic relevance of isolated MYC rearrangements was weaker than that of
BCL2 isolated translocations, but was probably limited by the rarity of the rearrangements. Seven of eight patients
with double hit lymphoma had the germinal center subtype with poor outcome. The germinal center subtype
patients with isolated BCL2 translocations had significantly worse outcome than the patients without BCL2
rearrangements (P=0.0002), and their outcome was similar to that of patients with the activated B-cell subtype
(P=0.30), but not as bad as the outcome of patients with double hit lymphoma (P<0.0001). Bcl-2 protein overex-
pression was associated with inferior outcome in patients with germinal center subtype lymphoma, but multivari-
ate analysis showed that this was dependent on BCL2 translocations. The gene expression profiling of patients
with BCL2 rearrangements was unique, showing activation of pathways that were silent in the negative counter-
part. BCL2 translocated germinal center subtype patients have worse prognosis after rituximab-CHOP, irrespective
of MYC status, but the presence of combined gene breaks  significantly overcomes the prognostic relevance of iso-
lated lesions.
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BCL2 translocations are more frequently found in the GCB
subtype, whereas 18q21 locus amplification is more com-
mon in the ABC subtype of DLBCL.3,8,10
The prognostic significance of BCL2 amplification or
translocations in de novo DLBCL in the era of CHOP ther-
apy alone, without rituximab, was controversial.11-20 Some
data on the prognostic significance of BCL2 aberrations in
patients treated with R-CHOP have recently become
available, with two studies reporting no influence of BCL2
gene rearrangements on the survival of DLBCL
patients.21,22 On the other hand, the concomitant presence
of t(14;18) or variants and MYC rearrangements, referred
to as double hit lymphomas, has consistently been associ-
ated with adverse outcome in DLBCL patients treated
with R-CHOP.23-25
Bcl-2 protein expression seems only partially related to
BCL2 gene abnormalities as analyzed by fluorescence in
situ hybridization (FISH), as Bcl-2 is expressed in a greater
number of DLBCL cases than in those tumors carrying
t(14;18)(q32;q21).10-12 Indeed, in the absence of BCL2
translocations, amplification of 18q21 and/or activation of
the nuclear factor κB (NF-κB) pathway can cause Bcl-2
protein overexpression.26 The prognostic significance of
Bcl-2 expression is also controversial, and comparison
between different studies is hampered by the choice of
different cut-offs of positive cells, and by the variability of
treatments. In patients treated with R-CHOP, Bcl-2 protein
did not correlate with outcome,5,27 since the addition of rit-
uximab seemed to improve survival of Bcl-2-positive
patients,28-30 apparently eliminating the gap between Bcl-2-
positive and Bcl-2-negative patients found in the pre-ritux-
imab era. This result does, however, appear to be contra-
dicted in a very recent study in which Bcl-2 expression in
GCB-DLBCL was associated with poorer outcome.22
The goal of this study was to investigate the prognostic
value of BCL2 gene aberrations and Bcl-2 expression in a
large number of patients with de novo DLBCL, uniformly
treated with R-CHOP, for whom MYC and GEP character-
ization was available.
Design and Methods
Patients
We studied 327 cases of previously untreated de novo DLBCL,
diagnosed between January 2002 and October 2009, and collected
as part of the International DLBCL Rituxan-CHOP Consortium
Program Study. These cases were analyzed for Bcl-2 protein
expression, and BCL2 and MYC gene abnormalities, and gene
expression profiling (GEP) was performed. All cases were
reviewed by a group of hematopathologists (SMM, MAP, MBM,
AT, and KHY), and the diagnoses were confirmed based on World
Health Organization classification criteria. Patients with transfor-
mation from low grade lymphoma, those with composite follicu-
lar lymphoma, primary mediastinal large B-cell lymphoma, pri-
mary cutaneous and primary central nervous system DLBCL were
excluded from the analysis due to the unique biological features of
these types of lymphoma. All patients were adults who were neg-
ative for human immunodeficiency virus and had sufficient clini-
cal data and clinical follow-up. Patients in this study were treated
with R-CHOP (n=291, 89%) or R-CHOP-like regimens (n=36,
11%; CHOP scheme adopting different anthracyclines i.e.
novantrone or epirubicin). All patients with advanced stage dis-
ease received six (92%) or eight (8%) cycles, every 21 days, with
or without radiotherapy for residual disease or initial bulky dis-
ease; localized cases received at least three cycles followed by
radiotherapy or six cycles without radiotherapy. The current study
was approved by each of the participating centers’ Institutional
Review Boards, and the overall collaborative study was approved
by the Institutional Review Board at The University of Texas MD
Anderson Cancer Center in Houston, Texas, USA.
Immunohistochemistry for Bcl-2 and cut-off 
determination
Bcl-2 protein expression was evaluated in all patients using a
monoclonal anti-Bcl-2 antibody (Clone-124, Dako, Carpinteria,
CA, USA) and standard immunohistochemical methods. The for-
malin-fixed, paraffin-embedded tissue slides underwent deparaf-
finization and heat-induced antigen retrieval techniques. An
endogenous biotin-blocking kit (Ventana) was used to decrease
background staining. Following antigen retrieval and primary anti-
body incubation, the reaction was completed in a Ventana ES
instrument using a diaminobenzidine immunoperoxidase detec-
tion kit (Ventana). Immunoreactivity was determined without
knowledge of the patients’ survival, clinical data, or GEP data. The
samples were analyzed independently by a group of four
hematopathologists/pathologists in addition to the hematopathol-
ogist of each of the contributing centers, and disagreements were
resolved by joint review at a multi-headed microscope. An average
of 300-400 cells in four to five fields were counted in the tissue
microarray cores. A percentage of tumor cell staining ≥50% was
considered positive after receiver operating characteristic (ROC)
curve analysis was implemented to assess the discriminatory accu-
racy of Bcl-2 protein in recognizing patients with different overall
survival (OS) and progression-free survival (PFS). The 50% value
was established from the analysis of the area under the ROC curve
(AUROC) and had the maximum specificity and sensibility for OS
and PFS discrimination in our patients (AUROC=0.564, P=0.017
for OS and AUROC=0.564, P=0.015 for PFS).31
Gene expression profiling analysis 
RNA was extracted from 327 formalin-fixed, paraffin-embed-
ded tissue samples using a HighPure Paraffin RNA Extraction Kit
(Roche Applied Science). Fifty nanograms of RNA were tran-
scribed into cDNA, linearly amplified using the WT-Ovation™
FFPE System (Nugen), and biotin-labeled using FL-Ovation™
cDNA Biotin Module V2 (Nugen) in all cases. For GeneChip
hybridization, 5 μg of WT-Ovation amplified cDNA were applied
to HG-U133 Plus 2.0 GeneChips (Affymetrix) and hybridized
overnight. GeneChips were washed, stained, and scanned using
the Fluidic Station 450 and GeneChip Scanner 3000 (Affymetrix)
according to the manufacturer’s recommendations. For data analy-
sis and classification, the microarray DQN (trimmed mean of dif-
ferences of perfect match and mismatch intensities with quantile
normalization) signals were generated and normalized to the
quantiles of beta distribution with parameters p=1.2 and q=3 as
previously described.32 A Bayesian model was also utilized to
determine the class probability. The classification model was built
on the 47 paired formalin-fixed, paraffin-embedded tissue sample
dataset previously generated with a confidence rate of 90-100% in
fresh frozen tissue and 92-100% in formalin-fixed, paraffin-
embedded tissue. The same methodology developed during this
study has been validated and demonstrated to be applicable by
using the LLMPP dataset in the Gene Expression Omnibus (GEO)
database GSE#10846 that has 181 CHOP-treated and 233 R-
CHOP-treated DLBCL patients with fresh-frozen samples.3,4
Fluorescence in situ hybridization for BCL2 and MYC
gene rearrangements
FISH was performed using a locus-specific identifier BCL2 dual-
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color, break-apart probe (07J75-001 from Vysis, Downers Grove,
IL, USA) on paraffin-embedded tissue sections according to the
Vysis protocol. FISH for the MYC gene was performed with a
locus-specific identifier IGH/MYC/CEP 8 tri-color, dual fusion
probe (DFP, 05J75-001 from Vysis) and, due to shortcomings of the
former in identifying alternative (non-IGH) C-MYC rearrange-
ment partners, a locus-specific identifier MYC dual-color, break-
apart probe (BP, 05J91-001 from Vysis). Abnormal FISH signals
were recorded as percentage of cells showing an abnormality. The
cutoff score to consider a case rearranged (‘‘breaks’’) was the mean
+ 3 SD of split nuclei in reference cases (i.e., >3%). A high-level of
18q21 amplification was defined as the presence of either more
than ten gene signals or tight clusters of at least five gene signals.
Sections of five tonsils were used as controls. To assess repro-
ducibility, the results obtained by two observers were compared
in a blinded fashion in 80 cases, showing a perfect agreement for
breaks (κ=1) and an excellent agreement for gains (κ=0.91). 
Validation set
To validate our observations in predicting survival in an inde-
pendent series of cases, we analyzed a second group of 120
archival DLBCL cases studied similarly to the first cohort except
for MYC analysis that was not available (GCB 49%, ABC 40%,
unclassified 11%; BCL2 translocations in 18%; Bcl-2 overexpres-
sion in 54%). All these patients had been treated with R-CHOP
and the same selection criteria as those for the first cohort were
applied. The clinical characteristics at presentation of the patients
in the validation set were not significantly different from those of
the patients in the test set.
Statistical analysis 
Following pre-defined criteria,33 PFS was measured from the
time of diagnosis to the time of progression or death from any
cause. OS was measured from the time of diagnosis to last follow-
up or death from any cause. Only patients with a follow-up of
longer than 12 months were included in the survival analysis. The
actuarial probabilities of PFS and OS were determined using the
Kaplan–Meier method, and differences were compared using the
log-rank test. A Cox proportional-hazards model was used for
multivariate analysis. The χ2 test or Mann-Whitney test was
applied to assess differences between variables. The interobserver
agreement for FISH was assessed using the κ statistic; a κ value of
>0.75 implied excellent agreement. All statistical calculations,
except for ROC and the κ statistic which were performed with
SPSS 18.0 (SPSS Inc., Chicago, IL, USA), were conducted using
StatView (Abacus Concepts, Berkeley, CA, USA).
Results
Patients’ characteristics and outcome
The median age of the patients at diagnosis was 62
years (range, 18–86). Their clinical characteristics are
reported in Table 1. The average follow-up time for sur-
vivors was 48 months (median 46; range, 12-113). Only
322 of the 327 patients were included in the survival
analysis, since a minimum follow-up of 12 months was
required by the study criteria. The 3-year OS rate of the
322 patients from this study cohort was 70%±3%, and
the 3-year PFS rate was 58%±3%. Of the common, clini-
cally relevant prognostic variables, International
Prognostic Index (IPI) risk group 0-2 versus 3-5 (P<0.0001),
and all the single variables included in the IPI were signif-
icantly associated with OS and PFS. Patients with the GCB
subtype had significantly better 3-year OS and PFS com-
pared to patients with ABC subtype lymphoma (OS:
75%±4% versus 65%±5%, respectively, P=0.003; PFS:
65%±4% versus 52%±4%, respectively, P=0.003).
BCL2 and MYC genes in the subgroups defined 
by gene expression profiling
Sixty patients (18.3%) had DLBCL with BCL2 gene
translocations, and 50 (15.3%) had BCL2 gene amplifica-
tions. The presence of BCL2 translocations was not asso-
ciated with any clinical prognostic variable at diagnosis,
except for Ann Arbor Stage (70% versus 49% with stage
III-IV, P=0.004), as shown in Table 1. As expected, BCL2
translocations were significantly associated with the GCB
subtype (84%, P<0.0001), while gains were present most-
ly in the ABC subtype (70%, P<0.0001). MYC rearrange-
ments were identified in 27 patients (8%), and eight of
them had a concomitant BCL2 translocation, representing
double hit lymphomas. Seven of these eight (88%)
patients with double hit lymphoma had GCB-DLBCL, and
all progressed or relapsed within 12 months from start of
therapy (Figure 1A). Patients with MYC breaks were
equally distributed among patients with or without BCL2
translocations (P=0.11), but were more frequent (16 cases,
70%) within the GCB subtype group.
The OS and PFS rates of patients with BCL2 transloca-
tions were similar to those of patients without BCL2
translocations, irrespectively of MYC status. When we
restricted the analysis to the GCB subtype, patients with
BCL2 translocations alone, in the absence of MYC breaks,
had a significantly worse outcome than GCB patients with-
out BCL2 translocations (3-year PFS of 53% versus 76%,
respectively; P=0.0002). The outcome of patients with
BCL2 rearranged GCB subtype was similar to that of the
patients with the ABC subtype of DLBCL (52%, P=0.30),
but still better than that of the patients with double hit lym-
phomas (P<0.0001, Figure 1A). This finding was confirmed
in our validation set of 120 patients, in which BCL2 translo-
cations, while not being predictive in the cohort as a whole
(P=0.05 for OS; P=0.11 for PFS), was an adverse variable in
the GCB subtype (P=0.01 for both OS and PFS, Figure 1B).
The presence of MYC breaks alone in the 19 patients
without concomitant BCL2 translocations was not associ-
ated with impaired PFS (P=0.70) or OS (P=0.66) in the
whole cohort, but was associated with inferior OS
(P=0.03), but not PFS (P=0.22), in patients with GCB-
DLBCL (only 9 with isolated MYC breaks). As shown in
Figure 1A, BCL2 and MYC rearrangements each con-
tributed with a cumulative pejorative hit to the outcome
of GCB-DLBCL patients, while they had no prognostic
impact in patients with ABC-DLBCL. 
BCL2 gains were not prognostic in any of the subgroups
of patients. Particular consideration of high-level amplifi-
cations was of no additional prognostic value.
Bcl-2 protein expression, clinical characteristics, 
fluorescence in situ hybridization and gene 
expression profiling
None of the common clinical characteristics of our
patients at the time of presentation was significantly asso-
ciated with Bcl-2 protein expression except age, with older
patients more often being Bcl-2 positive (≥60 years old,
P=0.02). Bcl-2 protein expression in GEP- and FISH-
defined subgroups is shown in Figure 2. The number of
positive cells in patients with the BCL2 translocation was
distinctly higher (range, 10-100%; median 90%) than in
BCL2 translocations in diffuse large B-cell lymphoma
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patients without the BCL2 translocation (range, 0-100%;
median 60%).
Bcl-2 protein expression was significantly associated
with worse PFS (P=0.01) and OS (P=0.02) in the whole
cohort, but when patients were divided according to GEP-
defined subtypes, we observed that higher Bcl-2 expres-
sion was associated with significantly inferior PFS in the
GCB subgroup (P=0.04), but not in the ABC subgroup
(P=0.57), as shown in Figure 3. 
Figure 4 illustrates that Bcl-2 protein expression was not
prognostic in patients with or without BCL2 transloca-
tions, indicating that Bcl-2 expression cannot be used as a
surrogate of t(14;18) and its variants in assessing prognosis
(see also multivariate analysis). These curves were
obtained after excluding patients with double hit lym-
phomas from the analysis, since these are associated with
Bcl-2 overexpression (Figure 2), and might have represent-
ed a confounding variable. When we tested this finding in
the validation set of patients, for whom MYC analysis
was not available, the prognostic relevance of Bcl-2 pro-
tein expression appeared again dependent of BCL2 gene
status, even though statistical significance between sub-
groups was not reached due to low numbers (58 patients
with GCB-DLBCL, 20 with BCL2 translocations, only 3
not expressing Bcl-2). 
Multivariate analysis
Multivariate analysis of all 137 patients with the GCB
subtype of DLBCL showed that BCL2 translocations (HR
0.40, 95% CI: 0.18-0.89; P=0.02), but not Bcl-2 expression
(HR 1.01, 95% CI: 0.45-2.21; P=0.98), MYC breaks (HR
0.25, 95% CI: 0.10-0.59; P=0.001), and IPI score (HR 0.41,
95% CI: 0.20-0.84; P=0.01), were independently associat-
ed with patients’ outcome. Results were not modified
after each molecular feature was computed with age as a
continuous parameter.34 However, both BCL2 and MYC
rearrangements lost their predictive power when patients
with double hit lymphomas were excluded, signifying
that the presence of double gene breaks overcomes the
significance of the isolated lesions in GCB-DLBCL.
C. Visco et al.
258 haematologica | 2013; 98(2)
Table 1. Clinical characteristics and treatment response of 327 DLBCL patients treated with R-CHOP, divided according to the presence of BCL2
gene rearrangements [t(14;18) or its variants].
Overall t(14;18) No translocations P value
or variants
N. % N. % N. %
Patients 327 100 60 100 267 100
Median age 62
≥60 190 58 34 57 156 58 0.80
<60 137 42 26 43 111 42
Gender
Female 140 43 32 53 108 41
Male 187 57 28 47 159 59 0.07
Stage
I-II 154 47 18 30 136 51 0.004
III-IV 173 53 42 70 131 49
Lactate dehydrogenase
Normal 103 36 19 37 84 36 0.94
Elevated 182 64 33 63 149 64
Extranodal sites*
0-1 243 79 43 77 200 79 0.66
>1 65 21 13 23 52 21
Performance Status
0-1 204 86 37 88 167 86 0.62
>1 34 14 5 12 29 14
IPI risk group
0-2 176 64 33 65 143 64 0.90
3-5 99 36 18 35 81 36
Gene expression profiling
GCB 139 47 48 82 91 38 <0.0001**
ABC 138 46 9 16 129 54
Unclassified 21 7 1 2 20 8
Bcl-2 protein
Negative 116 39 10 18 106 45 0.0002
Positive 178 61 47 82 131 55
MYC gene abnormalities
No break 300 92 52 87 248 93 0.11
Break 27 8 8 13 19 7
Data regarding lactate dehydrogenase (n=285), involvement of extranodal sites (n=308), Performance Status (n=238), IPI risk group (n=275), GEP (n=298), and Bcl-2 protein expres-
sion (n=294), were not available for all patients; *Primary nodal DLBCL (no extranodal site involved, 42% of patients) had no significant association with BCL2 translocations com-
pared to patients with one or more extranodal sites involved (P=0.43); **refers to the comparison between GCB and ABC. Clinical and biological characteristics of 327 DLBCL
patients treated with R-CHOP.  The patients were stratified according to the presence of BCL2 translocations.
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BCL2 translocations in diffuse large B-cell lymphoma
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Figure 1. Overall survival and progression-free survival of patients with DLBCL according to (A) the presence of BCL2 translocations alone
or concomitant MYC breaks stratified by GEP-defined subgroups; (B) BCL2 translocations stratified with GEP subgroups in the validation set.
DHL: double hit lymphoma.
Figure 2. Box plot graphs
for the distribution of Bcl-2
expression in 327 patients
with DLBCL according to
GEP and FISH analysis.
Reported P values were
calculated with the Mann-
Whitney test. Only signifi-
cant differences are report-
ed. SD= standard devia-
tion. (A) Bcl-2 protein
expression in GEP-defined
subgroups; (B) Bcl-2 pro-
tein expression in correla-
tion with BCL2 and MYC
gene aberrations in GEP-
defined subgroup. UC:
unclassified; DHL: double
hit lymphoma.
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Differential gene expression between patients 
with germinal center B-cell lymphoma with 
or without t(14;18)
Four-hundred and forty-four genes were found to be
differentially expressed (>1.5 fold and P<0.005) in
DLBCL patients with or without BCL2 translocations
including both GCB and ABC subtypes. In the GCB
group, however, only 43 genes were differentially
expressed among patients with and without BCL2
translocations (Figure 5A). Most of these genes (72%)
were informative. As expected, BCL2 was highly
expressed in the translocated cases, as was the MME
(CD10) gene. BCL11A, an oncogene that is located at
2p16.1 beside the c-REL locus and that functions as a
transcriptional repressor, was highly expressed in
patients with BCL2 translocated tumors. Neither
BCL11A nor c-REL was increased in the ABC subgroup
with BCL2 translocations (Figure 5B).
Interestingly, a number of genes overexpressed in the
BCL2 translocated group are involved in the control of
angiogenesis and the inflammatory response (AIMP1,
PPIA, and ALOX), while others are involved in promoting
apoptosis or regulating B-cell signaling (STK17A, RAL-
GPS2, NCOA3, STRBP, and ZNF117).35-37
C. Visco et al.
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Figure 3. Overall sur-
vival and progression-
free survival of patients
with DLBCL according
to Bcl-2 protein expres-
sion in GEP-defined
subgroups. 
Figure 4. Overall survival and progression-free survival of 103 patients with GCB-DLBCL, stratified according to Bcl-2 protein expression and
BCL2 translocations. Patients with double hit lymphoma were excluded from this analysis. For OS: P=0.79 and P=0.58 between A and B,
and C and D, respectively; P=0.23 and P=0.04 between A and D, and B and C, respectively. For PFS: P=0.61 and P=0.94 between A and B,
and C and D, respectively; P=0.01 and P=0.01 between A and D, and B and C, respectively.
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Discussion
We addressed the clinical impact of BCL2 aberrations
and their relationship to Bcl-2 protein expression in a large
series of patients with DLBCL homogeneously treated
with R-CHOP, with known MYC gene status and molec-
ularly characterized according to GEP analysis. We were
able to establish the role of the BCL2 gene in different sub-
types of DLBCL, irrespectively of concomitant MYC aber-
rations. We found that isolated BCL2 translocations, in the
absence of MYC breaks, were associated with a poor out-
come in the subset of patients with GCB-DLBCL, and that
the prognosis of these patients was similar to that of
patients with ABC-DLBCL. The concomitant presence of
MYC breaks (double hit lymphoma) further worsened the
outcome of these patients. The role of Bcl-2 protein
expression appeared dependent on its association with
BCL2 translocations, as outlined by multivariate analysis
and survival curves (Figure 4). Finally, BCL2 gains, more
common in ABC-DLBCL, did not affect prognosis.
As determined by FISH break apart probe analysis, the
overall frequency of BCL2 translocations in de novo DLBCL
was 18.3%. The BCL2 translocations were almost exclu-
sively associated with GCB-DLBCL, found in 34.5% of
cases (Table 1), similarly to other reports.3,4,8,38 Nine cases
of ABC-DLBCL harbored BCL2 translocations (one was a
double hit lymphoma), and the presence of BCL2 translo-
cations in ABC DLBCL did not influence the PFS of these
patients. The preferential occurrence of BCL2 rearrange-
ments in the GCB subgroup, and its impact on survival of
this subgroup, suggests that BCL2 translocations might be
an important and initial event in the pathogenesis of GCB
DLBCL. 
The impact of BCL2 translocations on survival in our
series could not be explained by differences in the clinical
features of the patients because there was no association
between the presence of BCL2 translocations and IPI risk
groups (P=0.90, Table 1). Patients with GCB-DLBCL and
BCL2 translocations had an outcome that was similar to
that of patients with ABC-DLBCL, while the remaining
patients with GCB-DLBCL without BCL2 translocations
had a very good PFS (Figure 1). The prognostic role of
BCL2 translocations appeared independent of the con-
comitant presence of MYC aberrations, being present also
when patients with double hit lymphoma were excluded
from the analysis (Figure 1A). However, the presence of
double gene breaks (double hit lymphoma) conferred a
significant further worsening to the outcome of patients
BCL2 translocations in diffuse large B-cell lymphoma
haematologica | 2013; 98(2) 261
Figure 5. Gene expression profile and representative FISH analysis of DLBCL patients. (A). Gene expression profile of 139 GCB-DLBCL
patients stratified according to the presence or absence of BCL2 translocations; (B). Gene expression profile of 80 DLBCL patients with BCL2
translocations stratified between GCB-DLBCL (n=78) and ABC-DLBCL (n=12); (C). Representative FISH of BCL2 amplification (upper image)
and translocation (lower image) using a locus-specific identifier BCL2 dual-color break-apart probe.
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with isolated BCL2 or MYC lesions. Confirming previous
findings,23-25 we were able to show in our series the syner-
gistic clinical effect of combined activation of MYC (pro-
moting cellular proliferation) and BCL2 (blocking cellular
death), which was associated with the GCB subtype, and
was the strongest prognostic variable together with IPI
risk group in this subgroup of patients, as outlined by our
multivariate analysis and shown in Figure 1A. 
In this series, Bcl-2 protein was overexpressed in half of
the patients with GCB-DLBCL and in 72% of patients
with ABC-DLBCL (Figure 2), consistent with other
series.18,39 However, Bcl-2 overexpression had prognostic
value only in the GCB subtype, as already observed by
others in the era of R-CHOP therapy.22,40 In the present
study we have shown that the prognostic effect of Bcl-2
expression within the GCB subgroup is related to the con-
comitant presence of BCL2 translocations. No impact of
Bcl-2 protein expression was present in patients with or
without BCL2 translocations (Figure 4), a finding obtained
after excluding patients with double hit lymphoma. 
Iqbal et al.22 recently published a similar analysis to our
study in patients classified by GEP analysis, confirming
that the prognostic significance of Bcl-2 protein is
observed in the GCB subset rather than in ABC-DLBCL.
Differently from our findings, in their study BCL2 translo-
cations were not adverse in the GCB subset. We believe
that several factors may have contributed to the different
prognostic impact of BCL2 translocations in our study
compared to Iqbal’s study. First, the number of patients
with GCB-DLBCL and BCL2 rearrangements in Iqbal’s
study was apparently low to drive conclusions on the
independence of the association between BCL2 transloca-
tions and Bcl-2 protein expression, similarly to what we
observed in 20 such patients in our validation set.22
Secondly, Bcl-2 protein expression in Iqbal’s study was sig-
nificantly associated with adverse clinical prognostic fac-
tors (stage III-IV, elevated lactate dehydrogenase, high IPI
risk group) in GCB-DLBCL, which was not the case in our
study. Finally, no mention was made about exclusion of
possibly confounding DLBCL subtypes such as double hit
lymphoma, primary cutaneous or primary central nervous
system DLBCL. We also acknowledge that different find-
ings in the literature regarding BCL2 rearrangements or
protein expression could very well be related to lack of
uniformity between different studies in terms of Bcl-2
staining and scoring. Moreover, patients’ characteristics in
the different series, differences in the management of the
cases as they were not in clinical trials, data collection
regarding outcome, and sometimes short follow-up times
may also have contributed to different results. 
Our GEP analysis revealed that patients with BCL2
translocations substantially differed with respect to impor-
tant recurrent oncogenic events, which may contribute to
the adverse outcome of the subgroup of GCB-DLBCL
patients with BCL2 translocations. Up-regulation of the
BCL11A gene occurred exclusively in the group of patients
with BCL2 translocations (Figure 5). BCL11A cooperates
with c-REL in B-cell lymphomas,19,41 and amplification of
the c-REL locus has already been reported to be more com-
mon in the GCB-DLBCL subtype, in which it was found
in 16% of cases,3 but without further characterization.
These cases might correspond to our subgroup of GCB-
DLBCL with BCL2 translocations overexpressing BCL11A.
The c-Rel/NF-κB pathway can also be constitutively acti-
vated in the ABC subgroup,3,4,26 in which it is supposed to
be responsible for the relatively poor outcome in this sub-
group. On the other hand, the prognostically favorable
GCB gene-expression signature is notable because the
GCB subgroup otherwise has decreased activity of the NF-
κB signaling pathway. Hence, the activation of the NF-κB
pathway in our subgroup of GCB-DLBCL characterized
by BCL2 translocations and adverse outcome warrants
further studies specifically addressing BCL11A amplifica-
tions in this subset of GCB-DLBCL. 
We confirm that the outcome of GCB-DLBCL patients
should be interpreted in the context of abnormalities of
the MYC and BCL2 genes. While the MYC rearrangement
is quite rare, it is rarely found as the sole genetic abnormal-
ity, and its clinical relevance is mainly related to a double
hit mechanism, BCL2 rearrangements are present in a con-
siderable fraction of patients with the GCB subtype who
have similar outcomes to those of patients with the ABC
subtype. Our results confirm that the GCB and ABC sub-
types of DLBCL have distinct pathogeneses, and support
the rationale for further classification of different sub-
groups.
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